The European Commission (EC) has granted marketing authorisation for Swiss-based Ferring Pharmaceuticals’ Rekovelle (follitropin delta), a human recombinant follicle stimulating hormone (human rFSH).

Rekovelle is used in controlled ovarian stimulation to develop multiple follicles in women who undergo assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.

Derived from a human cell line, it is the first rFSH treatment to be administered with an individualised dosing regimen.

Ferring Pharmaceuticals president of executive board and Michel Pettigrew said: “Ferring has a long-standing commitment to scientific advancement in reproductive health.

“As a research-driven company, we believe that by focusing on innovative and personalised approaches, we can continue to lead the way in fertility treatments and help women to plan their futures as mothers.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Ferring has a long-standing commitment to scientific advancement in reproductive health."

The individualised dosing regimen of Rekovelle is based on a woman’s serum anti-Müllerian hormone (AMH) level, as well as her body weight.

By predicting a woman’s ovarian response to gonadotrophin stimulation, it can also help guide the dosing of fertility treatments.

The EC approval is based on a clinical data package, including results from the Phase III ESTHER trials.

The randomised, assessor-blind, controlled, multicentre Phase III ESTHER trials involved patients in 11 countries, and more than 2,000 cycles of controlled ovarian stimulation.

Data revealed that individualised treatment with Rekovelle had similar results for the co-primary endpoints of ongoing pregnancy and implantation rates.